chevron_leftBack
As of 24 April 2025, Filament Health Corp. has a market cap of $5.72M USD, ranking #35134 globally and #1551 in Canada. It ranks #3529 in the Healthcare sector, and #730 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$5.72MUSD
7.92M CAD
Enterprise Value
$5.62MUSD
7.8M CAD
Revenue (TTM)
$445.3KUSD
616.68K CAD
EBITDA (TTM)
-$2.66MUSD
-3.69M CAD
Net Income (TTM)
-$3.59MUSD
-4.97M CAD
Company Profile
Country (HQ)
Sector
Healthcare
CEO
Benjamin Lightburn
open_in_new
Employees
13
Website
filament.health
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 40% | 50% | 0% | -29% | -38% | -50% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
FH
Filament Health Corp
ISIN: CA31685W1068
Shares Out.:
Shares Outstanding:
261.794M1
Shares Float:
120.884M2
|
0.0350 CAD | |
|
FLHLF
Filament Health Corp
ISIN: CA31685W1068
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.0219 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Filament Health Corp.
Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company in Canada. Its leading drug candidates comprises PEX010 oral psilocybin, PEX020 oral psilocin, and PEX030 sublingual psilocin. The company also develops AEX010 ayahuasca, which is in preclinical stage; and AEX020 monoamine oxidase inhibitor and is in preclinical stage. In addition, it provides in-house human clinical trials, as well as license technology to drug developers, researchers, and other licensed parties. Filament Health Corp. is headquartered in Burnaby, Canada.
